MGIC Investment Corporation reports Q1 2026 results today against a backdrop of improving price momentum but an analyst community that sees limited upside from current levels. The stock has gained 13% over the past month to $29.13, yet the Street's consensus target of $29.00 tells the whole story: the rally has essentially closed the gap to fair value.
The positioning backdrop is relaxed, not stressed. Short interest runs at 3.9% of the float — notable but not elevated — and edged up roughly 11% over the past three weeks after a step-change around April 9 before trimming back slightly on the week. Borrow conditions pose no meaningful constraint: cost to borrow has ticked up 22% over the past week but remains negligible at 0.51% APR, and availability is extraordinarily loose, with the lending pool far from under pressure at current utilization levels well below last year's highs. Options positioning has shifted markedly toward calls over the past week. The put/call ratio has dropped to 15.5, well below its 20-day average of 31.7 and more than a standard deviation beneath that mean — a shift that reflects call activity picking up in line with the recent price recovery rather than any defensive hedging.
The analyst debate is less a debate than a measured standoff. KBW and Barclays both raised targets to $29 in early April — right where the stock now trades — while maintaining neutral-equivalent ratings (Market Perform and Equal-Weight respectively). Those moves followed UBS trimming its target to $28 in March from $29.50. The message across all three is consistent: the mortgage insurance business is stable, but at current multiples the stock is appropriately priced. The P/E has expanded 0.8 points over the past 30 days to 9.2x, and price-to-book has moved up 0.1 to 1.09x — modest re-ratings that reflect the broader stock recovery rather than a fundamental reassessment. The EV/EBIT factor ranks in the 82nd percentile, suggesting the valuation is not stretched by historical standards even if the Street sees no obvious catalyst for further multiple expansion.
One nuance worth noting is insider selling in the weeks ahead of this print. CEO Tim Mattke sold 139,202 shares on April 2 at $26.49 — a $3.7 million transaction — while President/COO Sal Miosi sold shares across two separate transactions in March and April. Net insider activity over the past 90 days reflects substantial award grants alongside those sales, so the headline net figure is positive, but the discretionary selling from the CEO and COO into the recent weakness is a detail the market will weigh. Closest peers NMIH, ESNT, and RDN all gained on the week — up 4.3%, 1.8%, and 1.5% respectively — suggesting sector tailwinds rather than MTG-specific drivers behind the move.
Today's print is ultimately a test of whether the earnings trajectory can justify the valuation gap the stock just closed, or whether analyst neutrality at $29 proves to be a ceiling.
See the live data behind this article on ORTEX.
Open MTG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
